Teriflunomide in patients with multiple sclerosis

The article discusses the prospects for the use of the new drug teriflunomide for the treatment of patients with relapsing-remitting multiple sclerosis. By now, phase II and III clinical trials are completed which demonstrated good tolerability, efficacy and relative safety of teriflunomide. The TEM...

Full description

Bibliographic Details
Main Authors: N. Y. Lasch, A. N. Boyko
Format: Article
Language:Russian
Published: Remedium Group LLC 2015-12-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/177
Description
Summary:The article discusses the prospects for the use of the new drug teriflunomide for the treatment of patients with relapsing-remitting multiple sclerosis. By now, phase II and III clinical trials are completed which demonstrated good tolerability, efficacy and relative safety of teriflunomide. The TEMSO and TOWER trials showed a decrease in the incidence of relapse which was a reason for hospitalization (by 59 and 37%, respectively), as well as in the incidence of exacerbations requiring treatment with corticosteroids (by 34 and 36%, respectively).
ISSN:2079-701X
2658-5790